Strota/ Newsroom/ 2026-06-22

DRREDDY is trading +1.3% higher on at day's high

Strota Newsroom · session of 2026-06-22 · mid-session report, as of 11:39 IST — updates after the close · DRREDDY stock page →

Dr. Reddy's Laboratories Ltd. (DRREDDY) is trading +1.3% higher at ₹1,288.60 with 1 signal firing. Here is what the exchange data shows as of 11:39 IST.

Dr. Reddy's Laboratories is trading at ₹1,288.60 as of 11:39 IST, up 1.3% for the session and sitting at the day's high of ₹1,288.70. The stock opened with a modest 0.12% gap and has steadily climbed from the session low of ₹1,272.80, outperforming the Nifty 50 which is up 0.61% at the same time.

The positioning data offers little to explain the move. There is no fresh futures positioning information available, and the relative volume at 0.48 suggests trading activity is running well below normal — roughly half the average turnover for this time of day. Without options flow or open-interest changes to examine, the footprint of institutional or speculative positioning remains invisible.

On the institutional front, the evidence shows no block deals in the last 30 days and no streak of consecutive buying or selling sessions. No promoter or insider filings have appeared in the past 60 days. The stock appears to be moving without the visible hand of large informed players stepping in today.

Technically, Dr. Reddy's sits in a mixed but generally constructive posture. The RSI reads 52.1, neither overbought nor oversold. Price holds above both the 50-day and 200-day moving averages, though it has not triggered a golden cross. The stock trades 6.34% below its 52-week high and 12.21% above its 52-week low. Returns over the past week are flat at 0.71%, while the one-month return shows a decline of 1.42%. The watch zone flags ₹1,288.70 as the immediate level to watch — a sustained close above this signals continuation, while a slip back below ₹1,272.10 would flip the near-term bias bearish.

The news tape carries one potentially relevant item: a CNBC TV18 headline from an hour ago reports that Nomura expects the shares to rise 37% on renewed focus on branded generics and the consumer business. This appears to be the most proximate catalyst for today's bid. Other recent headlines include routine technical commentary and older earnings-related coverage, including a Zacks report from 39 days ago noting that Q4 earnings and revenues missed estimates.

The data shows no single obvious catalyst beyond the brokerage commentary, and the low volume suggests this is not a broad participation move. What is visible is a modest gap-up that has held and extended, with price pressing against session highs in a market that is itself grinding higher. Whether the Nomura view translates into sustained buying will likely depend on whether ₹1,288.70 gives way with volume, or whether the level rejects the advance as it has done in earlier sessions.

The numbers

Signals that fired

Technical context

Volume ran at 0.5× its 20-day average; rsi(14) sits at 52; price is 6.3% from the 52-week high; trading above the 50-dma and 200-dma.

Recent headlines

Sources

Keep digging

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.